SCHEMBL7437649

SCHEMBL7437649

Clc1nc(OCc2ccccc2)c2[nH]cnc2n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 8/20 0.71
MGMT P16455 5/20 0.71
CDK1 P06493 3/20 0.71
CCNB1 P14635 3/20 0.71
CCNA2 P20248 3/20 0.71
CDK2 P24941 3/20 0.71
CCNA1 P78396 3/20 0.71
LMNA P02545 2/20 0.71
CYP1A2 P05177 1/20 0.71
CYP3A4 P08684 1/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C9 P11712 1/20 0.71
TSHR P16473 1/20 0.71
NFKB1 P19838 1/20 0.71
CYP2C19 P33261 1/20 0.71
BLM P54132 1/20 0.71
PMP22 Q01453 1/20 0.71
CDC7 O00311 3/20 0.63
DBF4 Q9UBU7 3/20 0.63
HTR2C P28335 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14542385 0.84 PIN1 (0.72) PIN1MGMTCDK1CCNB1CCNA2
6-O-Benzylguanine SCHEMBL61740 0.83 PIN1 (1.00) PIN1MGMTCDK1CCNB1CCNA2
SCHEMBL8959024 0.83 PIN1 (0.71) PIN1MGMTCDK1CCNB1CCNA2
6-O-Benzylguanine SCHEMBL31517079 0.83 PIN1 (1.00) PIN1MGMTCDK1CCNB1CCNA2
6-O-Benzylguanine SCHEMBL4631744 0.82 PIN1 (0.97) PIN1MGMTCDK1CCNB1CCNA2
SCHEMBL3303850 0.80 PIN1 (0.66) PIN1MGMTCDK1CCNB1CCNA2
SCHEMBL15759317 0.79 PIN1 (0.64) PIN1MGMTCDK1CCNB1CCNA2
SCHEMBL1404475 0.78 CDC7 (1.00) PIN1MGMTCDK1CCNB1CCNA2
6-O-Benzylguanine SCHEMBL4869639 0.78 PIN1 (0.88) PIN1MGMTCDK1CCNB1CCNA2
SCHEMBL7437643 0.77 PIN1 (0.46) PIN1MGMTCDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195498-A1 INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME UNIWERSYTET WARSZAWSKI (PL) 2025-06-19 US claimed
WO-2023177312-A2 INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME UNIWERSYTET WARSZAWSKI (PL) 2023-09-21 WO claimed
US-4801710-A Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives MERCK & CO., INC. (US) 1989-01-31 US claimed
EP-0184473-A1 Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives MERCK & CO. INC. (US) 1986-06-11 EP claimed
US-20250195498-A1 INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME UNIWERSYTET WARSZAWSKI (PL) 2025-06-19 US disclosed
WO-2023177312-A2 INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME UNIWERSYTET WARSZAWSKI (PL) 2023-09-21 WO disclosed
EP-0538332-B1 POLYCYCLIC GUANINE DERIVATIVES SCHERING CORP (US) 1997-07-23 EP disclosed
US-5393755-A Hypotensive agents, enzyme inhibitors SCHERING CORPORATION (US) 1995-02-28 US disclosed
EP-0538332-A1 POLYCYCLIC GUANINE DERIVATIVES. SCHERING CORP (US) 1993-04-28 EP disclosed
WO-1991019717-A1 POLYCYCLIC GUANINE DERIVATIVES SCHERING CORPORATION (US) 1991-12-26 WO disclosed
US-4801710-A Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives MERCK & CO., INC. (US) 1989-01-31 US disclosed
EP-0184473-A1 Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives MERCK & CO. INC. (US) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195498-A1 INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME PNP, ITPA, NUDT5 PIN1 816/4885MGMT 572/4885CDK1 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.